Nanobiotix (NASDAQ:NBTX) Shares Gap Up – What’s Next?

Nanobiotix S.A. – Sponsored ADR (NASDAQ:NBTX)’s stock price gapped up before the market opened on Friday . The stock had previously closed at $38.95, but opened at $41.67. Nanobiotix shares last traded at $40.2640, with a volume of 16,603 shares.

Wall Street Analysts Forecast Growth

Several research analysts have recently commented on the stock. TD Cowen reaffirmed a “buy” rating on shares of Nanobiotix in a report on Thursday, March 12th. UBS Group increased their price objective on shares of Nanobiotix from $3.50 to $30.00 and gave the stock a “neutral” rating in a research note on Friday, May 1st. Weiss Ratings reissued a “sell (d-)” rating on shares of Nanobiotix in a report on Tuesday, April 21st. Guggenheim lifted their target price on Nanobiotix from $26.00 to $36.00 and gave the company a “buy” rating in a research note on Thursday, April 2nd. Finally, HC Wainwright reaffirmed a “buy” rating on shares of Nanobiotix in a report on Monday, May 18th. Four equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, Nanobiotix has an average rating of “Moderate Buy” and an average target price of $37.33.

Nanobiotix Stock Up 2.8%

The business has a 50 day simple moving average of $39.58 and a 200-day simple moving average of $31.55.

Institutional Trading of Nanobiotix

Several hedge funds have recently bought and sold shares of NBTX. Millennium Management LLC acquired a new position in Nanobiotix during the 4th quarter valued at about $390,000. Royal Bank of Canada grew its position in Nanobiotix by 2,000.0% in the 4th quarter. Royal Bank of Canada now owns 2,625 shares of the company’s stock worth $61,000 after purchasing an additional 2,500 shares during the last quarter. Finally, Marshall Wace LLP bought a new position in Nanobiotix in the 4th quarter worth about $220,000. 38.81% of the stock is currently owned by institutional investors.

About Nanobiotix

Nanobiotix is a clinical-stage biotechnology company headquartered in Paris, France, specializing in the development of novel nanopharmaceuticals to improve cancer treatment. The company’s lead product, NBTXR3, is a first-in-class radioenhancer composed of hafnium oxide nanoparticles designed to amplify the effect of radiotherapy on tumor cells while sparing surrounding healthy tissue. Nanobiotix has established clinical programs across multiple cancer indications, including soft tissue sarcoma, head and neck cancer, and hepatocellular carcinoma.

Since its inception, Nanobiotix has advanced NBTXR3 through pivotal trials and secured CE Mark approval in Europe for the treatment of soft tissue sarcoma.